Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CDK inhibitors
Biotech
Genentech pays $850M upfront for Regor's CDK inhibitors
Genentech is taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients failed by existing options.
Nick Paul Taylor
Sep 30, 2024 5:30am
Kronos launches second round of layoffs in 5 months
Mar 8, 2024 10:35am
BeiGene offers up $1.3B in biobucks for preclinical cancer drug
Nov 21, 2023 7:13am
Bayer inks Cedilla cancer deal to join pack chasing Pfizer
Jun 1, 2023 7:30am
Syros targets KRAS-mutant cancer with CDK7 inhibitor
Sep 20, 2021 11:30am
G1 Therapeutics' chemo companion nabs speedy FDA review
Aug 17, 2020 10:40am
